Clinical Trial Update: Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067 [Phase 1]

View source ↗

Summary

Phase 1 study of BIA 9-1067 in Parkinson's disease evaluating tolerability, pharmacokinetics and pharmacodynamics completed with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• BIA 9-1067

Snippet

Sponsor: Bial - Portela C S.A. | Conditions: Parkinson's Disease (PD) | Phase 1 | Status: COMPLETED | Results posted: 2015-01-09